Humana Surges 12.4% on Revised Outlook as $1.62B Volume Ranks 46th in Market Activity

On July 30, 2025, Humana (HUM) surged 12.40% with a trading volume of $1.62 billion, ranking 46th in market activity. The rally followed a revised full-year outlook driven by reduced Medicare Advantage membership declines and stronger-than-expected earnings. Management now forecasts adjusted EPS of $17, up from $16.25, with revenue guidance raised to at least $128 billion. The company attributed the improved performance to CenterWell Primary Care’s patient growth of 50,000–70,000 and higher prescription volumes.

Humana’s updated projections contrast with broader industry challenges, as peers grapple with persistent healthcare cost pressures. The firm’s medical cost ratio of 89.7% aligned with estimates, signaling better cost control than anticipated. Despite a recent legal setback regarding Medicare quality ratings, the latest guidance has tempered investor concerns, with shares showing resilience despite a 1.3% year-to-date decline.

Backtested data from 2022 to present reveals a strategy of buying top 500 high-volume stocks and holding for one day generated a 166.71% return, significantly outperforming the benchmark’s 29.18%. This highlights liquidity-driven approaches’ potential to capitalize on short-term market dynamics, with excess returns of 137.53% and a 31.89% CAGR underscoring the strategy’s effectiveness in leveraging volume trends.